4.8 Article

American Cancer Society Prostate Cancer Survivorship Care Guidelines

Journal

CA-A CANCER JOURNAL FOR CLINICIANS
Volume 64, Issue 4, Pages 226-249

Publisher

WILEY
DOI: 10.3322/caac.21234

Keywords

prostate cancer; survivorship; clinical care; follow-up; guidelines; primary care; quality of life; survivorship care plan; long-term effects; late effects; care coordination

Categories

Funding

  1. Centers for Disease Control and Prevention [5U55DP003054]
  2. VA HSR&D Career Development Award [2 (CDA 12-171)]
  3. American Cancer Society/Centers for Disease Control and Prevention for the National Cancer Survivorship Resource Center project
  4. Mick RadioNuclear
  5. Amgen
  6. Sanofi-Aventis
  7. Janssen
  8. Astellas/Medivation
  9. Actavis Pharmaceuticals
  10. Astellas Pharmaceuticals
  11. American Cancer Society/Centers for Disease Control and Prevention
  12. Pfizer Inc/Pfizer Foundation Global Health Partnerships Program
  13. American Cancer Society funds
  14. ArborMetrix, Inc

Ask authors/readers for more resources

Prostate cancer survivors approach 2.8 million in number and represent 1 in 5 of all cancer survivors in the United States. While guidelines exist for timely treatment and surveillance for recurrent disease, there is limited availability of guidelines that facilitate the provision of posttreatment clinical follow-up care to address the myriad of long-term and late effects that survivors may face. Based on recommendations set forth by a National Cancer Survivorship Resource Center expert panel, the American Cancer Society developed clinical follow-up care guidelines to facilitate the provision of posttreatment care by primary care clinicians. These guidelines were developed using a combined approach of evidence synthesis and expert consensus. Existing guidelines for health promotion, surveillance, and screening for second primary cancers were referenced when available. To promote comprehensive follow-up care and optimal health and quality of life for the posttreatment survivor, the guidelines address health promotion, surveillance for prostate cancer recurrence, screening for second primary cancers, long-term and late effects assessment and management, psychosocial issues, and care coordination among the oncology team, primary care clinicians, and nononcology specialists. A key challenge to the development of these guidelines was the limited availability of published evidence for management of prostate cancer survivors after treatment. Much of the evidence relies on studies with small sample sizes and retrospective analyses of facility-specific and population databases. (C) 2014 American Cancer Society.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available